Spinal muscular atrophy is a rare and lethal genetic disease, and most children live less than 20 months. Recently, researchers have used new gene therapy to develop a biotech drug SpinrA. zA. SpinrA. zA. , By injecting drugs around the patient's spinal cord, restored motor function to nearly half of the 73 patients. The researchers concluded that this new gene therapy will be used for the spinal cord. Breakthrough in the treatment of muscular dystrophy. Which of the following, if true, would best support the above argument. ['The FDA has approved the marketing of this new drug.', 'None of the patients in the control group returned to motor function.', 'The specific program design of the study is more scientific and reasonable.', 'This gene therapy can also be used for the treatment of other diseases.']